Company Snapshot: Johnson & Johnson

Johnson & Johnson
Revenues	2010: 61.6 billion USD
	2009: 61.9 billion USD
	2008: 63.7 billion USD
Revenue CAGR (2008 - 2010)	-1.70%
Net profit (2010)	13.3 billion USD
Net profit CAGR (2008 - 2010)	1.50%
R&D expenses	2010: 6.8 billion USD (11.1% of revenues)
	2009: 7.0 billion USD (11.3% of revenues)
	2008: 7.6 billion USD (11.9% of revenues)
Number of employees	115,500
Location of headquarters	US
Principal areas of business	Skin and hair care products, acetaminophen products, pharmaceuticals, surgical and diagnostic equipment
Segmental revenue breakdown (2010)	Medical Devices and Diagnostics: 39.9%; Pharmaceutical: 36.4%; Consumer: 23.7%
Geographical revenue breakdown (2010)	US: 47.8%; Europe: 25.2%; Asia Pacific & Africa: 18.0%; Western Hemisphere excluding US: 9.0%
Top 3 biopharmaceutical drugs (2010 Sales)	Remicade: 4.6 billion USD; Procrit/Eprex: 1.9 billion USD; Risperdal Consta: 1.5 billion USD
Recent Acquisition Summary	Acquired partial stake in 23andMe Inc.
	Acquired Micrus Endovascular Corporation, a manufacturer of medical devices for treatment of cerebral
	Acquired RespiVert Ltd, a small molecule drug discovery company for treatment of chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.
	Acquired partial stake in Astute Medical Inc for 26.5 million USD.
	Acquired Acclarent Inc, a medical technology company in the field of ENT, for 785.0 million USD.
Recent License Deals Summary	Agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System 2010.
	Agreement with Watson Laboratories Inc to distribute an authorized generic version of CONCERTA.
	Agreement with Merck & Co Inc for marketing rights for CAEYLX outside the US
	Agreement with Diamyd Medical AB to develop and commercialize GAD65 antigen-based therapy.
	Expansion of licensing agreement with the Grünenthal Group to register, manufacture and commercialize
	Tapentadol in additional regions, including selected Asia Pacific, Latin American, African, and New European
	countries including Turkey and Greece.